Bristol Myers Squibb
Revenue 2016: $19.4bn2025: $48.2bn
Counted on the 10 of 15 questions that could be answered from the filings. A second reader, working blind from the same quotes, arrived at 71.4 with 7 answered.
A study note on how the company fits a fixed list of questions. Not a view on the shares, not a recommendation. How the marks are made
Position heldThe author holds no shares in this company. Stated on 21 November 2026.
01Quiet leadership
60 of 100 2 of 3 answeredThe chief executive credits others and owns the misses
Could not assess
The last two letters to shareholders and what the chief executive says alongside results.
How all 12 companies answered thisThere are no earnings call transcripts and only the 2025 letter. The pieces of it that were found ("2025 was a year of disciplined execution across", and credit to the "workforce") are neutral and own no miss.
No checked quote is on file for this question. The company's filings at sec.gov
The chief executive grew up inside the company
4 of 5
The biography in the proxy statement.
How all 12 companies answered thisThe proxy statement lists Head of U.S. Commercial Markets (2015-2017) as his earliest role at the company, and chief executive from November 2023. That is about 8 years inside first.
Bristol Myers Squibb, Chief Executive Officer (November 2023-present)
Head of U.S. Commercial Markets (2015-2017)
No restructuring theatre
2 of 5
Restructuring programmes, company-wide rebrands and strategy overhauls in ten years of annual reports.
How all 12 companies answered thisTwo programs are shown: the restructuring that followed the Celgene acquisition (at least $3.0 billion of synergies) and the 2023 Restructuring Plan (charges of $747M, $603M and $442M). There is also an ongoing strategic productivity initiative.
Through our Celgene acquisition restructuring activities, we realized at least $3.0 billion of synergies annually resulting from cost savings and avoidance.
Selling, general and administrative expenses decreased by $1.1 billion or 14%, primarily due to cost savings from the Company's ongoing strategic productivity initiative and lower acquisition-related cash settlements of unvested stock awards, partially offset by higher investments in new product launches.
02People before plans
67 of 100 3 of 3 answeredA real system for developing people
3 of 5
The people section of the annual report and the proxy statement.
How all 12 companies answered thisThe proxy statement claims leadership development programs in 2025. It gives no numbers for participation, promotion or training.
In 2025, the company invested in leadership development programs designed to strengthen capabilities across all levels of the organization.
These programs provide employees with opportunities to develop new skills and take on expanded responsibilities.
Executives stay
4 of 5
Filings that report officer departures over the last three years.
How all 12 companies answered thisFilings on officer changes show two executive officers leaving in the last three years: Hirawat (chief medical officer, left 1 November 2025) and Leung (General Counsel, retiring 2025).
Effective August 1, 2025, Dr. Hirawat no longer served as EVP and Chief Medical Officer, Head of Development, and transitioned into an advisory role through November 1, 2025, the date of his departure.
Ms. Sharon Greenlees, Senior Vice President and Controller, will assume another role at the Company, effective February 15, 2024.
The best people on the biggest opportunities
3 of 5
Who runs the main growth area, and where they came from.
How all 12 companies answered thisNo named senior leader is tied to running the Growth Portfolio. The heads of RayzeBio and Cell Therapy are not linked to it in the filings quoted.
Executive Vice President, Chief Commercialization Officer (2018-2023)
03Narrow focus
60 of 100 2 of 3 answeredBest in the world at something
Could not assess
Market position claims and the sources given for them.
How all 12 companies answered thisThe filings give only an unmeasured claim of "leadership in" multiple myeloma and an aim for "a leading franchise in IO". There is no market share figure and no claim to be number one.
No checked quote is on file for this question. The company's filings at sec.gov
The same business for a decade
5 of 5
The business description from ten years ago beside the latest one.
How all 12 companies answered thisThe 2016 and 2025 business descriptions carry the same mission sentence ("discover, develop and deliver innovative medicines that help patients prevail over serious diseases"), with oncology, immunology and cardiovascular in both. Neuroscience is a new therapeutic area inside the same biopharmaceutical business.
Bristol-Myers Squibb Company (which may be referred to as Bristol-Myers Squibb, BMS, the Company, we, our or us) is a global specialty biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
We are focused on the following core therapeutic areas: oncology, immuno-oncology, immunoscience, cardiovascular diseases, fibrosis and genetically defined diseases.
A clear way of making money per unit
1 of 5
Whether management reports profit or revenue per customer, store, shipment or similar.
How all 12 companies answered thisNo measure of profit or revenue per unit was found. Searches for per patient, per customer, revenue per and per unit returned nothing. The filings give only shares of sales at portfolio level.
No checked quote is on file for this question. The company's filings at sec.gov
04Discipline and straight talk
80 of 100 2 of 3 answeredCareful with capital
3 of 5
Arithmetic on ten years of figures reported to the SEC: the change in share count and debt against free cash flow.
How all 12 companies answered thisArithmetic from SEC figures gives 3: share count down 9.7% in five years, debt 3.49 times free cash flow. Not lowered: no quote shows an acquisition above a fifth of the company's value at the time, and Karuna at $14.0 billion was below that line on the figures quoted.
Ten years of figures the company reported to the SEC. Its annual reports at sec.gov
Faces bad news squarely
Could not assess
The worst quarter or year of the last five, and what management said next.
How all 12 companies answered thisThe net loss of $11.9 billion in the first quarter of 2024 is put down to the $12.1 billion Karuna charge, and Cobenfy was later approved. No earnings call shows management naming a fix.
Found in the filings, but not enough to settle a mark:
On a GAAP and non-GAAP basis, Acquired IPRD increased to $12.9 billion from $75 million, primarily due to the Karuna asset acquisition and SystImmune collaboration.
Cobenfy is an antipsychotic with a novel mechanism of action and differentiated efficacy and safety, which was approved by the FDA on September 26, 2024 for the treatment of schizophrenia in adults.
Earnings backed by cash
5 of 5
Arithmetic: five years of free cash flow against reported profit, and whether results were ever restated.
How all 12 companies answered thisOver five years, free cash flow was 3.43 times net income, which gives a 5. The SEC filing list shows no restatement filing in the last 10 years. Enforcement actions were not checked.
Ten years of figures the company reported to the SEC. Its annual reports at sec.gov
05Steady compounding
80 of 100 1 of 3 answeredSteady growth, year after year
4 of 5
Arithmetic: years of falling revenue out of the last ten.
How all 12 companies answered thisRevenue fell in one of the last ten years, which gives a 4.
Ten years of figures the company reported to the SEC. Its annual reports at sec.gov
No pivots or short-lived programmes
Could not assess
Strategy statements across ten years of annual reports.
How all 12 companies answered thisThe filings show only the 2024 decision to stop work on one investigational compound (a $390 million write-down of in-process research, IPRD). There is no list of abandoned programs over ten years.
Found in the filings, but not enough to settle a mark:
In 2024, a $390 million IPRD impairment charge was recorded in Research and development expense following a decision to discontinue development of an investigational compound in connection with the prioritization of pipeline opportunities.
A widening lead
Could not assess
Arithmetic: operating margin in the last three years against the three before.
How all 12 companies answered thisThe figures on file give no arithmetic mark, and operating margin is missing for every year. No customer retention or market share data is quoted either.
Found in the filings, but not enough to settle a mark:
Our overall business mix is beginning to transform as our Growth Portfolio becomes a bigger component, representing 55% of our net sales in 2025 compared to 47% in the prior year.